Currently, 3 clinically validated biomarkers are US Food and Drug Administration (FDA) approved to predict patient response to ICI treatment; programmed death 1 ligand 1 (PD-L1) expression [2–6], microsatellite instability (MSI)/mismatch repair deficiency (dMMR) [5, 7], and tumor mutational burden [8]. This evidence concerns the gene CD274 and neoplasm.